SCHEMBL23208192

SCHEMBL23208192

O=C(Nc1ccc(C(F)(F)F)cc1)Nc1c[nH]c2ccc(-c3c(F)cccc3F)cc12

nearest known ligand 0.67

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ STING1 Q86WV6 7/20 0.67
▸ MTOR P42345 1/20 0.49
▸ TRPV1 Q8NER1 1/20 0.47
▸ EPHX2 P34913 1/20 0.47
▸ GOT1 P17174 1/20 0.47
▸ KDR P35968 2/20 0.46
▸ KIT P10721 1/20 0.46
▸ FLT3 P36888 1/20 0.46
▸ BAZ1A Q9NRL2 1/20 0.46
▸ RIPK1 Q13546 2/20 0.46
▸ MAPT P10636 2/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ HTT P42858 1/20 0.46
▸ RAB9A P51151 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ IGF1R P08069 1/20 0.44
▸ BRAF P15056 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23207917 0.88 STING1 (0.65) STING1MTOREPHX2GOT1KDR
SCHEMBL30195938 0.88 STING1 (0.65) STING1MTOREPHX2GOT1KDR
SCHEMBL23167861 0.87 STING1 (0.73) STING1TRPV1EPHX2GOT1KDR
SCHEMBL23208060 0.86 STING1 (0.65) STING1MTORTRPV1EPHX2GOT1
SCHEMBL30195880 0.86 STING1 (0.65) STING1MTORTRPV1EPHX2GOT1
SCHEMBL23208193 0.86 STING1 (0.65) STING1MTORTRPV1EPHX2GOT1
SCHEMBL23207916 0.85 STING1 (0.64) STING1MTORTRPV1EPHX2GOT1
SCHEMBL22803837 0.85 STING1 (0.77) STING1MTORTRPV1EPHX2GOT1
SCHEMBL23207945 0.85 STING1 (0.66) STING1MTORTRPV1EPHX2GOT1
SCHEMBL23207905 0.85 STING1 (0.63) STING1MTORTRPV1EPHX2GOT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230002320-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-01-05 — — US disclosed
US-20230002320-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-01-05 — — US disclosed
WO-2021067801-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY IFM DUE, INC. (US) 2021-04-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002320-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY STING1, CGAS, IRF3 STING1 1/4885MTOR 1583/4885TRPV1 671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback